Monthly masterminds, weekly updates, and networking with coliving operators worldwide.
Operator benchmarks, demand drivers, deal archetypes, regulatory pointers.
London is the largest European coliving market by total beds. London Plan H16 created an explicit pathway for purpose-built large-scale shared living. Compliance varies dramatically by borough, Article 4 directions, additional licensing, and SRA classifications create a genuinely fragmented per-borough regulatory and economic picture.
RevPAB (monthly)
£950-£1,300
ADR (per bed-night)
£32-£44
Stabilized occupancy
87-93%
Avg length of stay
7.5 months
Property OpEx ratio
55-65% of revenue
Cap rate range
4.5-6.0% (stabilized)
Target IRR
10-14% (5-year hold)
UCL, Imperial, KCL, LSE plus the City finance + tech + creative pool. Coliving captures the 'graduate-to-first-flat' transition. 6-9 month average stays at student-adjacent product.
Post-Brexit Skilled Worker visa drove ~150k inflow per year; many transit through coliving. Higher ARPU, 12+ month stays.
EU mobility ended in 2021 but legacy demand and Skilled Worker reroute continues. The base is shrunken vs. pre-Brexit but stabilizing.
Londoners priced out of solo flats. Often working professionals 25-35 looking for sub-£900/month inclusive. The Collective and Mason & Fifth target this segment explicitly.
~12,000+ operator-led coliving beds in Greater London. The Collective historically dominant; Mason & Fifth growing; Folk, Node, Vonder, Habyt all active. Pipeline of H16 schemes (50+ unit purpose-built) adding ~3,000 beds/year through 2027. Boroughs Greenwich, Lewisham, Wandsworth seeing most new supply; central boroughs (Westminster, Camden) supply-constrained.
Heavy institutional capital, Greystar Real Estate Partners, Round Hill Capital, M&G Investments all have explicit coliving allocations. Pension funds approaching coliving as a residential-adjacent asset class. GBP debt at 5.5-7.0% for stabilized assets. London is the European market most-comparable to NYC for institutional capital flow.
50+ unit scheme classified as sui generis. 18-36 month consenting timeline; £100k+ planning consultancy spend. Institutional-investor-compatible at scale. The Collective + Mason & Fifth template.
Buying SFH stock in Article 4 boroughs and applying for full planning. 12-24 week timeline, meaningful refusal rate. Suits mid-size operators with planning consultancy capacity.
Greenwich, Lewisham, Bromley, Bexley, Article 4 not in force, C4 conversion via permitted development. Fastest path to operating bed count. Capex per bed lower (£15-£25k vs £30k+ for central A4 conversions).
£950-£1,300 per bed per month at stabilization. Premium product (purpose-built H16, Mason & Fifth standard) reaches £1,400-£1,700. Mid-market HMO product £700-£950.
4.5-6.0% for stabilized institutional-grade H16 product. Mid-size HMO portfolios trade closer to 6.0-7.0%. London cap rates are among Europe's tightest reflecting demand depth.
Greenwich, Lewisham, Wandsworth, Bromley currently, Article 4 not in force, demand strong, transport adequate. Avoid Article 4 boroughs (Hackney, Camden, Tower Hamlets) for SFH-conversion strategies unless you're prepared for full planning timelines.
7.5 months blended. H16 large-scale schemes closer to 9 months. Mid-market HMO product 5-7 months. Skilled-worker-visa segment skews longer (12+ months).
Last reviewed: 2026-05-11. Benchmarks refreshed quarterly. Spot something out of date? Tell us.
We've supported operator and investor underwriting in 60+ countries.
